Citius Oncology, Inc. (CTOR) — Financial statements
Income statement, balance sheet, and cash flow for Citius Oncology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue & Gross Profit | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | |||||
| R&D Expenses | 6↑30.3% | 5↑16.1% | 4↓38.1% | 7 | |
| General & Administrative Expenses | 17↑9.3% | 16↑98.6% | 8↑175.8% | 3 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↑9.3% | 16↑98.6% | 8↑175.8% | 3 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 24↑14.3% | 21↑69.7% | 12↑24.8% | 10 | |
| Total Costs & Expenses | 24↑14.3% | 21↑69.7% | 12↑24.8% | 10 | |
| Operating Results | |||||
| Operating Income | -24↓14.3% | -21↓69.7% | -12↓24.8% | -10 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00↓100.0% | 10 | |
| EBITDA | -23↓14.2% | -21↓69.7% | -12 | 0.00 | |
| EBIT | -23↓14.2% | -21↓69.7% | -12↓24.8% | -10 | |
| Interest & Other Income | |||||
| Net Interest Income | -0.18 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.04 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.22 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -0.04 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -0.18 | 0.00 | 0.00 | 0.00 | |
| Income Before Tax | -24↓15.2% | -21↓69.7% | -12↓24.8% | -10 | |
| Income Tax Expense | 1↑83.5% | 0.58↑0.0% | 0.58↓50.0% | 1 | |
| Net Income & EPS | |||||
| Net Income from Continuing Operations | -25↓17.1% | -21↓66.6% | -13↓16.9% | -11 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -25↓17.1% | -21↓66.6% | -13↓16.9% | -11 | |
| Bottom-Line Net Income | -25↓17.1% | -21↓66.6% | -13↓16.9% | -11 | |
| EPS (Basic) | -0.34↓13.3% | -0.30↓57.9% | -0.19↓149.0% | -0.08 | |
| EPS (Diluted) | -0.34↓13.3% | -0.30↓57.9% | -0.19↓149.0% | -0.08 | |
| Weighted Average Shares | 73↑2.4% | 72↓20.0% | 89↓0.8% | 90 | |
| Weighted Average Diluted Shares | 73↑2.4% | 72↓20.0% | 89↓0.8% | 90 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.